NCT07422298

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	BMS-986278	Specified dose on specified days
DRUG	Placebo	Specified dose on specified days
DRUG	Moxifloxacin	Specified dose on specified days

Timeline

• Start date: 2026-02-19
• Primary completion: 2026-06-15
• Completion: 2026-06-15
• First posted: 2026-02-20
• Last updated: 2026-03-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study